Previous 10 | Next 10 |
Janux Therapeutics ( NASDAQ: JANX ) said it submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) seeking to start a trial of cancer drug JANX008 in humans. The company added that JANX008 is in development to treat EGFR-e...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today an...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platfor...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street’s version of playing...
Janux Therapeutics press release ( NASDAQ: JANX ): Q3 GAAP EPS of -$0.40. Revenue of $1.8M (+55.2% Y/Y) . For further details see: Janux Therapeutics GAAP EPS of -$0.40, revenue of $1.8M
-First patient dosed with JANX007 in first-in-human Phase 1 clinical trial in prostate cancer patients- -Interim clinical update from Phase 1 trial of JANX007 expected in 2H 2023- -IND application for EGFR-TRACTr (JANX008) remains on-track to be submitted in 2H 2022- ...
Shares of Janux Therapeutics (NASDAQ: JANX) , which specializes in immunotherapies to treat cancer, rose 33.1% this week, according to data from S&P Global Intelligence . The stock closed at $13.07 last Friday, opened at $13.27 on Monday, and climbed throughout the week, ris...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platfor...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short-squeeze stocks offer tremendous upside potential for people who laugh in the face of danger. Fundamentally, the concept involves betting against the pessimistic crowd with the aim of sparking a reactionary panic. Sinc...
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today annou...
News, Short Squeeze, Breakout and More Instantly...
Janux Therapeutics Inc. Company Name:
JANX Stock Symbol:
NASDAQ Market:
Janux Therapeutics Inc. Website:
The appointment of Eric Dobmeier and Natasha Hernday to the Board brings extensive operational and business development experience to support corporate and pipeline strategy Janux also announced the resignation of Jay Lichter, Ph.D., from the Board, and the appointment of current Board me...
2024-06-12 18:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...